However, our results suggest that some intrinsic properties of BCSC such as increased DNA-repair capacity, may contribute to resistance to PARP inhibitors, providing a basis for the relative failure of their clinical development in breast cancer. This evidence concerns the gene PARP1 and breast cancer.